Jonathan Deverill has over 20 years' experience in corporate and commercial work, including IPOs (AIM, UK Official List and Toronto Stock Exchange) and other securities offerings, M&A, takeovers and joint ventures, in addition to giving general corporate legal advice to a variety of clients. Over the years Jonathan has been involved in a significant number of cross-border transactions. Jonathan is one of the leading medical cannabis lawyers in the UK.
Jonathan acts regularly for both companies and their nominated advisors and brokers. Recent work includes advising on:
Several financings and acquisitions in the natural resources sector, including by way of a prospectus offering.
The acquisition of a specialist employee benefits business by a major international insurance broker.
Two secondary placings by shareholders of an AIM company.
Two Takeover Code offers by Canadian bidders.
Several "reverse takeovers".
A reduction of capital by an AIM-listed company.
The sale of a privately-held insurance group to a French acquiror.
The financing to construct a five-star hotel in Sierra Leone.
Several investments by an overseas real estate client.
A number of projects in the medical marijuana field.
Various issues under the EU Market Abuse Regulation.
Jonathan spent the first nine years of his career at Slaughter and May and, amongst other things, worked for three and a half years in the London office of Canadian firm Stikeman Elliott. He is a former member of the Legal Committee of the Quoted Companies Alliance, and speaks regularly on topics of interest in the corporate/commercial legal field.
Jonathan leads the firm's Canadian Desk. He is also a member of DAC Beachcroft's German Desk.
Jonathan has a first in law from Downing College, Cambridge and joined DAC Beachcroft on 1 April 2015.
Jonathan is described inLegal 500 UK 2013as "solutions-oriented", and is recommended in the 2016 edition in the category, 'Flotations: small and mid-cap'.